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
In this work, Process Analytical Technology (PAT) based approaches for controlling the polymor
phism and crystal size of a nonsteroidal antiinflammatory drug (Piroxicam) during batch cooling 
crystallization has been investigated. Previously obtained results regarding the crystallization behav
iour of the different polymorphs of Piroxicam in a small scale (100 ml) crystallizer have been used to 
design and to initiate the control approach described in this paper. The results of the present work 
demonstrated the challenge of reproducing the crystallization process with respect to the product pol
ymorphism at different scales. The solute concentration has been proved to be a critical parameter in 
determining the polymorphism of Piroxicam in the small scale crystallization experiments; however, 
the same operation parameters could not yield the same polymorph in the crystallization in 2L crystal
lizers. Both Direct Nucleation Control (DNC) and Supersaturation Control (SSC) have been proved to 
be effective at controlling the polymorphism of Piroxicam in seeded cooling crystallization, further
more, applying DNC also improved the particulate properties (larger crystal size). 

	: Crystallization, Polymorphism, Direct nucleation control (DNC), PAT, Piroxicam,  
Supersaturation control (SSC) 
 
 
As the complexity of new drugs is on the increase, issues with poor physicochemical properties are 
becoming a common obstacle in development
1
. One possibility of improving the performance of a 
drug candidate is to explore the various crystal forms of the compound, either on its own or in various 
complexes such as solvates or cocrystals2–4. Such exploration can be beneficial to drug development 
but these initial experiments are often carried out at a small scale. Additionally, although they do 
show what crystal forms the compound may exhibit and allow for investigations into the properties of 
these polymorphs, the control methods cannot simply be upscaled for production. 
Conducting reliable control of polymorphism throughout the developing and production process of an 
Active Pharmaceutical Ingredient (API) is a very challenging task. The issues with upscaling are an 
everincreasing challenge and failing to control the polymorphic form of an API can lead to foregoing 
development of a new product or, in the worst case, having a product on the market fail to reach quali
ty control standard. In fact, different polymorphs can have different dissolution rates, solubility and 
they can present very different stability during storage
5
. Since the formation of a specific polymorphic 
form in solution crystallization is sensitive to the process conditions, the results obtained from small 
scale experiments often cannot be reproduced in a larger scale process. Although valuable knowledge 
regarding the polymorphic nature as well as the crystallization mechanisms of the different poly
morphs can be obtained from small scale experiments, more sophisticated control strategies are re
quired to ensure the polymorphic control in larger scale productions. It has been reported that Super
saturation Control (SSC) allows for cooling profiles that leads to a relatively low supersaturation dur
ing batch crystallization. This helps to avoid secondary nucleation and therefore both reduces the risk 
of unwanted polymorphs appearing, and yields fewer fine particles in the product6–9.In cases where 
SSC is not sufficient to ensure the desired particle sizes or in cases where even a controlled cooling 
leads to unwanted polymorphs forming, controlled dissolution may be an option. This can either be 
done based on a fixed cooling profile where the temperature gradient is reversed to allow for the dis
solution of smaller particles, or various process analytical technology (PAT) tools can be used to se
lect when to start and stop the heating of the reactor. One technique is the use of particle counts from 
a Focused Beam Reflectance Measurement (FBRM) probe as this helps detecting when new crystals 
are being formed in the solution. When used in combination with seeding, this approach can be highly 
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effective as the seed crystals will generally ensure that the produced form is identical to the seed. At 
the same time, any new polymorphs that may nucleate out of solution would start out as small parti
cles and quickly dissolve during the heating steps. This method of control is known as Direct Nuclea
tion Control (DNC) and it has previously been used to control the crystallisation of organic com
pounds and to increase particle size and narrow the size distribution of the final product
10–15
.It was 
also found to reduce the amount of solvent inclusion
11
. That all contributes to a more efficient produc
tion with less variation in product quality. In the present work, this method is only applied to a single 
step batch reactor, however the concept have been expanded to multistage mixed suspension in a con
tinuous cooling crystallization
16,17
 as well as used for antisolvent and nonseeded crystallization
18
. 
The aim of this work is to demonstrate the effectiveness of PAT tools and PATbased feedback con
trol strategies in scaling up crystallisation processes for polymorphic compounds. Piroxicam was used 
as model compound. In our previous work, the crystallization of Piroxicam, which is a nonsteroidal 
antiinflammatory drug (NSAID), has been investigated in a small scale (100 ml) crystallization sys
tem19,20 Among the four polymorphs that Piroxicam can form21–23, only the polymorphic form I and II, 
which possess difference intermolecular hydrogen bonding and molecular orientations, have been ob
tained in our previous work along with the monohydrate form which was obtained in cooling crystal
lization from solutions with high water concentration. It has been observed that the formation of 
Piroxicam polymorphic form I, form II and the monohydrate depends on various operating parame
ters, such as the solvent composition, solute concentration, presence of certain additives, and the way 
supersaturation is created (cooling crystallization or antisolvent crystallization). A crystal form land
scape for Piroxicam was established to demonstrate the link between the solvent composition, solute 
concentration, and the phase of the nucleated crystals. In the present work, the results obtained in the 
100 mL scale system were compared to experiments conducted in a 2L crystallizer. Because of the 
impossibility to directly scale up the system seeding was conducted in the 2 L crystallizer to control 
the polymorphic purity of the end product. Finally, Direct Nucleation Control (DNC) and Supersatu
ration Control (SSC) strategies were tested. Both techniques were proved effective in controlling the 
polymorphic purity of Piroxicam during the experiments at large scale. 
 
 			
  !	"	
Piroxicam was purchased from Hangzhou Hyper Chemicals Limited, Zhejiang, China, and identified 
as the polymorphic form II. Piroxicam form I was prepared using antisolvent crystallization as de
scribed in previous literature
10
.Raman spectroscopy was used in the present work to identify the solid 
form of the crystals produced in the experiments. As the link between solid forms and Raman spectra 
have previously been confirmed24 by comparison with XRPD212223 this method was found to be ac
ceptable in determining crystal structure. All solvents were obtained from SigmaAldrich as 99.9% 
analytical grade solvents. For the antisolvent experiments, deionised water was used. 
All crystallization experiments were carried out in a 2L double walled glass reactor equipped with an 
overhead stirrer with a flat bottomed anchor type impeller and a thermostat and compared to experi
ments performed at 100 mL with magnetic stirring
10
. Antisolvent addition was achieved using a peri
staltic pump connecting the antisolvent container to a stainless steel tube at the top of the reactor, 
slightly offcentre to the stirrer to ensure that antisolvent would be added to the mixing vortex. 
The process analytical technology (PAT) tools used for process monitoring and control include an 
FBRM G400 0.5−2000 Cm (Mettler Toledo with iCFBRM software version 4.3), a ParticleView V19 
PVM (Mettler Toledo with iCPVM version 7.0), Mettler Toledo, a Zeiss MCS621 UV/vis spectropho
tometer with ATRUV/vis (Attenuated total reflectance –Ultraviolet/Visible) 190−720 nm Zeiss probe 
(Zeiss ProcessXplorer software version 1.3Build 1.3.1.30) and a RXN1 Raman immersion probe 
with 785 nm laser (Kaiser with iC Raman 4.1 software). The data from the FBRM and the Huber is 
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transmitted in realtime to the CryPRINS software (Crystallisation Process Informatics System) which 
allows real time temperature control and simultaneous monitoring of signals from different probes 
(FBRM, ATRUV/Vis, thermocouple, conductivity probes and pHmeter). The pre and post
processing of the data was done with Matlab R2012b and iC Raman 4.1. Filtered and dried crystals 
where analysed using a DXR Raman microscope (780nm, Thermo Scientific equipped with OMNIC 8 
software). XRPD were obtained with a MiniFlex600XRPD from Rigaku with data collected from 5° 
to 50° at 0.02° step size. Final product particle size distribution was determined using a Beckman 
Coulter LS 13320 laser diffraction particle size analyser. 
 
 #$	%
Antisolvent crystallization experiments were performed by dissolving Piroxicam in pure acetone at a 
ratio that would yield a saturated solution at 25°C. Water was then added to the reactor as the anti
solvent. Before the antisolvent crystallization started, the Piroxicamacetone solution was heated to 
35°C with stirring for 1 hour to dissolve all Piroxicam crystals. The temperature was then lowered to 
27°C and once stabilized; the addition of antisolvent was started. The feed rate of water to the reactor 
was fixed at 5 mL/min and samples were taken once nucleation was detected, and every 30 minutes 
thereafter. Samples were filtered, dried and analysed with the Raman microscope. Based on the initial 
results it was found that the first form to nucleate in significant quantities were form I, but transfor
mation into the monohydrate would happen as more water was added. To increase the yield of form I, 
experiments were also carried out where the addition of water was stopped once nucleation was ob
served and the temperature of the reactor was lowered to 10°C to force more API out of solution. 
 
& '			#			(%
Initially nonseeded cooling crystallization was carried out with low API concentration as this was 
previously found to produce form I crystals
19
 in a small scale 100 mL reactor with a solid state ther
mostat, allowing for fast and precise temperature control. However, this result was not possible to be 
reproduced in the 2L crystallizer, probably due to the less effective cooling system. It was then decid
ed to use polymorphic seeding to control the polymorphism of the product at this scale. The Piroxi
cam form I produced with the antisolvent crystallization was used as the seeds. Form I seed crystals 
were added at 2°C above the calculated saturation temperatures of each batch and with a seed load of 
10%. This allowed for faster production of large amounts of form I for later use in DNC and SSC ex
periments. 
 
) *	+	,'	-*+.''/
The direct nucleation control procedure has been widely used and explained in detail in the literature 
11,25–29. The technique uses both FBRM and CryPRINS to keep the number of total counts/s in the ves
sel constant during the batch crystallization process. The total counts/s measured by the FBRM is sent 
to CryPRINS and the temperature in the vessel is decreased if the measured total counts/s is lower 
than the set point range, or increased if it is higher (fine crystal particles are then dissolved). The total 
counts/s set point as well as the desired cooling and heating rate are set up in CryPRINS before start
ing the batch. Those parameters are usually system dependent and can be selected after a few prelimi
nary trials. 
For all experiments with active control, seed crystals were added to initiate the crystallization and 
DNC or SSC were then used to control the crystallization process. These two control strategy use two 
different features of the CryPRINS software and different inline process analytical technology (PAT) 
probes, FBRM for the DNC and ATRUV/Vis for the SSC strategy. In the DNC experiments present
ed in this work, seed crystals were added to saturated solutions and the FBRM total counts/s was left 
to stabilize with no temperature change. As the counts/s was found to be very low at the desired seed 
Page 5 of 20
ACS Paragon Plus Environment
Organic Process Research & Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
load, two setups were tried. The high counts DNC used a set point of 1000±100 counts/s and the low 
counts set point was determined by the initial count from seed crystals (approx. 200±100 counts). 
 
A calibrationfree approach was used to perform the seeded supersaturation control (SSC) experi
ments
8,30
. An inferential solubility curve for Piroxicam was obtained by slowly heating up a slurry of 
Piroxicam form I in acetone from 5.5°C to 50°C (0.01°C/min). The amount of Piroxicam and acetone 
in the crystallizer corresponded to the solubility of Piroxicam at 40 °C, so all the solid Piroxicam dis
solved at the end of the temperature profile. ATRUV/Vis spectra were recorded and a polynomial 
relation was found between the first derivative of the spectra signal (*) at 306 nm (correlated with the 
Piroxicam concentration) and temperature (). This correlation, * = (), corresponds to an inferential 
solubility curve expressed as UV signal versus temperature, instead of the classical concentration ver
sus temperature relationship, generally used in calibrationbased supersaturation control, leading to 
the use of arbitrary units (a.u.). 
  
The polynomial function measured is shown in Equation 1: 
 
 = . 
 ∙ 
 + .  ∙ + .  ∙ 
     (1) 
 
Equation (1) was implemented in the CryPRINS software and the experiments conducted followed the 
procedure: 
1. Solid Piroxicam was added to pure acetone (about 0.045 g/g acetone, corresponding to a satura
tion temperature of around 4345 °C) and the temperature was raised to 55 °C to allow complete 
dissolution of the solid; 
2. The temperature was kept constant at 50 °C for about half an hour and then the system was cooled 
down to about 41 °C; 
3. Crystalline seeds were added in an amount of about 10% of the total solid mass and the supersatu
ration control option in CryPRINS was switched on; 
4. The supersaturation set point was adjusted during the first minutes of control in order to guarantee 
a reasonable batch time. 
The supersaturation set point is calculated as the difference between the desired UV signal at a given 
temperature and the value of the inferential solubility of Piroxicam at that temperature. This value can 
be directly inserted in CryPRINS. Three different experiments were conducted in order to identify the 
optimal set point and seeding conditions. 
 
 0	
In previous work10 it was found that several methods can be used to control the polymorphism of 
Piroxicam in batch crystallization from acetone or mixtures of acetone and water. It has been ob
served that in cooling crystallization there is a strong link between the Piroxicam concentration and 
the polymorphism of the produced crystals. Higher solute concentration favoured the formation of 
form II, while form I was crystallized out from solutions with low concentration. The monohydrate 
Piroxicam was produced in cooling crystallization from acetone/water mixtures when water concen
tration exceeded 10%. It was also discovered that antisolvent crystallization in the Piroxicam
acetonewater system could produce form I regardless of the high water concentration in the system 
and the presence of form II seed crystals. Polymorphic seeding has been proved very effective in di
recting the nucleation of form I and II in cooling crystallization and therefore can be used to control 
the polymorphism of Piroxicam in crystallization process.  
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These previous studies were, however, conducted in small scale reactors and with limited options for 
monitoring the system during nucleation. This also meant that no form of feedback control could be 
implemented. Nevertheless, feedback control strategy might be necessary for robust production of one 
specific polymorph, especially in cases where different forms were known to compete. In the present 
work, preliminary experiments were firstly conducted to test if the concentrationdirected polymor
phic cooling crystallization experiments performed at 100 mL scale can be reproduced in a larger 
scale (2 L) crystallization system. The difficulties of upscaling crystallization processes are evident 
from the results as previous crystallization methodologies were found ineffective in the large scale 
system, where effective mixing and precise temperature control is more difficult to achieve. For this 
reason approaches for effective control of polymorphism were explored based on the indepth under
standing of the polymorphic crystallization mechanism obtained from the small scale experiments. 
 
&  (%
Preliminary cooling crystallizations were performed at low Piroxicam concentration, which was pre
viously found to favour the crystallization of form I at 100 mL scale. Although several experiments 
were conducted, and the operating conditions were close to what had previously been used at small 
scale, the produced crystals were consistently form II. A comparison of polymorphic behaviour along 
with operating conditions are shown in Table 1.This deviation from previous results could be attribut
ed to the varied cooling efficiency and mixing condition in the 2 L crystallizer, as well as the different 
batch of Piroxicam from a different supplier. It was noted that the temperature difference between set 
point and actual reactor temperature was wider for the large scale set up as would be expected. Fur
thermore, temperature gradient could not be followed below 10°C where the cooling rate would start 
to abate. This could be one reason for the unexpected form II as the system would stay in the metasta
ble zone for longer and at higher temperatures before nucleation occurred. Another likely factor was 
the change in raw material as the impurities contained in the material might affect the crystallization 
process. It was not possible to lower the concentration further to promote the crystallization of form I, 
as this would require subzero temperatures to even cross into a supersaturated range. It was therefore 
decided to use seeding to have robust control of the product polymorphism.  
 
	 1	$
1#			(%
Initial concentration 
[mg/g] 
Cooling rate 
[K/min] 
Polymorphic form nucleated at 
100 mL scale 2 L scale 
40 0.5 Form II Form II 
25 0.5 Form I Form II 
20 1.2 Form I Form II 
 
& #$	
As previously reported, antisolvent crystallization of Piroxicam from acetone solution was found to 
yield form I even if form II seeds were added to the reactor19. In some cases, the monohydrate form 
was also found during antisolvent experiments, although in very low quantities and only at 45°C. To 
further investigate the circumstances where monohydrate formation would become an issue, prelimi
nary experiments were carried out using PVM to monitor the formation of the crystals. Surprisingly, 
these experiments showed that all three forms were present at some point during the crystallization 
process. It has previously been reported that polymorph II form needle shaped crystals, whereas form 
I crystallizes in a cubic structure
20,31
. As the initial crystals observed from PVM were needle shaped, 
this would indicate that form II nucleated first shortly after the first particles become visible via PVM, 
several needle shaped crystals can be seen (Figure 1). As the water addition continues, cubic crystals 
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start to dominate the solution and no increase in the amount of needles was seen. As the water concen
tration increase, the monohydrate form starts to appear at the end of the batch (Figure 1) seeming to 
either grow on the surface of the cubic form I crystals or at least agglomerating to these particles. 
 
(	 213! (	 
#$				 ( 
 -/ 
 -/, -/4 -/
4	-	/,-
/!	
 
  
-/ -/
-/ -/
-	/ -
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The crystals were sampled during the antisolvent crystallization process and the microscope images 
(Figure 2) of the dried crystals showed that Piroxicam monohydrate formed on the surfaces of form I 
crystals.  
 
(	2!	(	
	(#$				-&56	/7.-)86/7
-9 6/	.
-9 6
	5	/
 
The use of antisolvent crystallization to produce form I proved to be problematic even when water 
addition was stopped prior to the monohydrate being observed. At 25 mg/g Piroxicam in acetone, only 
one experiment yielded form I without significant presence of the monohydrate form. In the two other 
attempts to produce form I, the monohydrate would be present to such an extent that the crystals were 
not deemed useful for subsequent seeding experiments (summarised in Table 2). The difference in the 
resulting product of the two experiments with antisolvent addition and cooling being identical is most 
likely due to differences in the amount of antisolvent that were added before nucleation was observa
ble. The form I crystals produced in the successful batch of antisolvent crystallization was used as 
seed crystals to investigate the feasibility of controlling the polymorphism of Piroxicam in cooling 
crystallization in the 2 L crystallizer system.  
 
	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		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

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Piroxicam concentration 
[mg/g] 
Antisolvent addition 
[ml/min] 
Cooling rate 
[K/min] 
Nucleated form 
25 5 No cooling Form I and mono
hydrate 
25 5 0.5 Form I 
25 5 0.5 Form I and mono
hydrate 
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It has been observed that seeding was effective for controlling polymorphism in the small scale 100 
mL crystallizer19. For this reason seeded cooling crystallizations were conducted also to crystallize 
Piroxicam form I in the 2 L crystallizer. Piroxicamacetone solutions saturated at 42°C (concentration 
of 45 mg/g) were prepared in order to have high yield of the process without risking boiling off of 
solvent. Both fixed rate cooling at 0.5°C/min and nonfixed (where the set point of the thermostat 
was immediately changed to 5°C once seed had been added) experiments were carried out to investi
gate the impact of cooling rates on the final product. The polymorphic form of the products was con
firmed to be that of form I using Raman spectroscopy in all cases, and with only variations in particle 
size (Figure 3) was noted for the different cooling profiles. Fast cooling yielded crystals with narrow 
size distribution, while the linear cooling rate at 0.5°C/min gave rise to particles with larger sizes but 
wider size distribution. The crystals produced with fast cooling were used as seed crystals for later 
experiments. This ensured a uniform and narrow size distribution with fast production runs, and with 
particle sizes small enough to still allow for crystal growth in a stirred batch reactor in the DNC ex
periments. 
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For the DNC experiments, Piroxicam crystals were first completely dissolved in acetone by heating 
the solution to 50°C. This accounts for the large spike in FBRM counts/s in Figure 4 in the first hour 
of the experiment until the crystals fully dissolve. Once crystals dissolved, the reactor temperature 
was lowered to 42°C and seed crystals (form I produced in seeded cooling crystallization with fast 
cooling) were added. After the crystals were dispersed in the liquid, the DNC parameters were set and 
control initialized. As it can be seen from Figure 4, the temperature followed the preset cooling pro
file but meanwhile would react to the counts/s from FBRM, which is considered to reflect the number 
of fine particles in the crystallizer. Comparing Figure 4 and Figure 5 it seems that the lower set point 
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for the FBRM count behaves more stable and at the end point, the FBRM count is lower than for the 
high DNC count. This is in agreement with the results for the particle size distributions where low 
DNC count also shows larger particles. Cooling would proceed if the counts/s from FBRM remained 
within a certain range, otherwise the temperature would increase if the counts/s from FBRM increased 
above the predefined limit, and cooling would continue until the counts/s dropped to the defined 
range. The control strategy is expected to minimize secondary nucleation, especially at later stage of 
the batch crystallization, and therefore it should lead to larger crystals with the desired polymorphism. 
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The inline images taken with PVM have suggested that form II could occasionally crystallize out 
during the process. However, the needle shape of these crystals, combined with a much smaller crys
tal size and lower density, led to an unforeseen control option. As the DNC would respond to higher 
particle counts by increasing temperature till the count was within set parameters again, the DNC 
ended up not only improving the particle size of the crystals greatly, but also helped controlling poly
morphism. As all form II crystals would contribute to the FBRM count, and only the smaller form I 
particles would, the system was in effect more sensitive to the formation of the form II crystals. The 
temperature of the reactor would thus be increased and particles would start to dissolve when form II 
started to nucleate. Therefore, even though form II crystals might compete with form I during the ex
periment, the DNC would constantly increase temperature when form II crystals nucleated and force 
them to dissolve again. The end result was form I crystals with a drastic increase in particle size, ob
servable even to the naked eye. From the results from the laser diffraction particle size analyser for 
the seed crystals and products from the DNC experiments (Figure 6), it is seen that the control ap
proach did have an impact on the crystal size distribution, although in the case of a high DNC count 
of 1000 counts/s the effect was far less pronounced as for the low count 180 count/s experiments. In 
both cases the polymorphic control was observed as even a count higher than what was detected from 
the seed crystals, where still far lower than the contribution of form 2 crystals in suspension. 
 
(	9'%	
		*+-:	

/
 
&> ''
Three different SSC experiments were performed in order to determine the best conditions to allow 
growth of Piroxicam form I. Table 3 shows the supersaturation setpoints used for the experiments 
and the supersaturation (SS) at the moment of seeding; initial solute concentration and seed load was 
the same for all experiments. The inline monitored concentration and supersaturation profile as well 
as the counts/s from FBRM for the three SSC experiments are shown in Figure 79. 
Figure 7 shows the results for Experiment 1 performed using a SS setpoint of 0.00031 a.u. As shown 
in Figure 7a and b the SS was kept at the desired setpoint for about 40 min after seeding; after that all 
SS was consumed by crystal growth and nucleation as shown in Figure 7c. 
  
Page 12 of 20
ACS Paragon Plus Environment
Organic Process Research & Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
  
	&2'		#	
			''			
Experiment Supersaturation set point 
(in UV signal a.u.) 
SS at seeding  
(in UV signal  a.u.) 
Final temperature (°C) 
1 0.00031 0.00039 10 
2 0.0002 0.00041 5 
3 0.00022 0.0002 10 
 
The total counts/s increased rapidly between the 80 and 100 min of the experiments as the supersatu
ration (from 5000 to over 20000 #/sec) was consumed by secondary nucleation of form I (as con
firmed by Raman microscopy at the end of the run). The decrease in total counts/s after 100 min (see 
Figure 7c) is due to both agglomeration of the nucleated crystals and partial sedimentation of the larg
er particles. 
Figure 10 a and b show the CLD distribution of the crystals at the end of Experiment 1, in comparison 
with the seeds, and a microscopic image of the crystals. The final CLD shows the presence of fine 
particles indicating secondary nucleation during the experiment, while the microscopic image shows 
presence of agglomeration (Figure 10b). It is clear that this SS set point promotes secondary nuclea
tion over growth; therefore, in Experiment 2 and 3 lower supersaturation set points were tested. 
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Experiment 2 was conducted with similar seeding conditions compared to Experiment 1(SS at seeding 
was 0.00041) but using a lower SS set point. The system took around 20 min for the supersaturation 
to  reach the SS set point, after which the level of supersaturation was kept close to the set point for 
about 50 min before finally decreasing to 0 as shown in Figure 8b. Secondary nucleation is still pre
sent but the maximum total counts/s is lower compared to Experiment 1 (16000 #/sec instead of over 
20000 #/sec), similarly to the total amount of fines, as shown in the final CLD reported in  
Figure 10a. A decrease in the total counts/s due to crystal agglomeration (similarly to Experiment 1) 
can be observed at the end of the run, as shown in Figure 8c. However this decrease is lower for Ex
periment 2 compared to Experiment 1, probably because of the lower number of fines nucleated dur
ing the run (less fines are agglomerating determining a higher final value of the total counts/s). 
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Figure 9 shows the results obtained for Experiment 3. In this case, a supersaturation set point of 
0.00022 was used and seeding was carried out at a SS level slightly lower than the SS set point 
(0.0002 a.u.). As shown in Figure 9 b and c this is the longest run and the SS set point was kept con
stant for about 175 min after seeding. However, an increase in total counts/s due to secondary nuclea
tion is still present although less significant than that in Experiment 1 and 2 (the final value is around 
12500 #/sec). Also, agglomeration of the fines happened, as proved by the decrease in total counts/s at 
the end of the profile and the microscopic image of Figure 10 d. 
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It is worth noticing how, despite the clear presence of secondary nucleation, only Form I was detected 
by Raman spectroscopy at the end of all experiments, in contrast with the DNC experiments that 
showed nucleation of Form II crystals during the runs. This is probably due to the lower supersatura
tion imposed by the SSC during these experiments, in contrast with the DNC ones. Such lower super
saturation prevented nucleation of form II crystals favouring secondary nucleation of Form I instead. 
In conclusion, SSC allowed growth of Form I crystals in a shorter time compared to DNC and without 
polymorphic transformation. However, this strategy couldn’t minimize secondary nucleation, and ag
glomeration of the fines resulting in a broader CLD and lower mean size compared to the crystals 
produced with DNC. 
 
 
The complex nature of polymorphic control during crystallization process development and scaling up 
has been demonstrated in the present work. Although the previous investigation in the 100 ml crystal
lization system has suggested a strong link between the solute concentration and the nucleation of the 
polymorphs of Piroxicam, this result could not be reproduced in the 2L crystallizer. The simple cool
ing experiments did not yield the expected form, and even the antisolvent crystallization, previously 
found to be a very robust method for producing form I crystals, only worked for a single run. The 
seeding experiments proved to be the most reliable way to produce form I in large quantities; this is in 
(a) 
(b) 
 
(c) 
 
(d) 
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agreement with the results obtained in the small scale experiments. The use of DNC proved to be a 
very effective method for significantly increasing the size of the crystals. Furthermore, the additional 
effect of polymorphic control when DNC was employed proved to be a great benefit. In fact, the ap
pearance of form II crystals indicated that without DNC, this form might start competing with form I 
when trying to increase particle size simply with very slow cooling.  
Seeded SSC experiments were also performed in order to grow pure form I. The final polymorphic 
purity was confirmed by Raman microscopy showing how this strategy allowed obtaining pure form I 
at the end of the run. However, SSC was less effective on producing larger crystals, less number of 
fine particles as well as less agglomerates were formed when DNC was applied to control the crystal
lization process.  
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